Welcome to our dedicated page for ESAB Corporation news (Ticker: $ESAB), a resource for investors and traders seeking the latest updates and insights on ESAB Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ESAB Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ESAB Corporation's position in the market.
ESAB announced a 33% increase in its quarterly cash dividend, from $0.06 to $0.08 per share, payable on July 12, 2024. The Company's President and CEO, Shyam P. Kambeyanda, highlighted the successful execution of strategic goals and strong cash flow generation. ESAB , founded in 1904, is a premier industrial compounder based in North Bethesda, Maryland.
ESAB announced record first-quarter sales and margin performance, reporting a 1% increase in sales and a 2% increase in core organic growth compared to the previous year. The company also reported $61 million in net income and $1.00 diluted earnings per share. ESAB is focused on driving growth and margin expansion through its ESAB Business Excellence strategy. The company strengthened its balance sheet with a successful bond offering and completed the acquisition of Sager S.A. and announced an agreement to acquire SUMIG Ltda. ESAB's outlook for full-year 2024 includes expected total core sales growth of 1.5% to 3.5% and core adjusted EBITDA of $500 to $520 million.